Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 104.09

-1.3%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2754)	6/5/2012 9:43:52 AM
From: scaram(o)uche	of 3202

Good question.... old paper, but these guys ought to know your answer by now (and were obviously leaning to "independent"). Pseudo Biologist probably knows the answer...... ncbi.nlm.nih.gov CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (snip) For example, it has been shown that CTLA-4-B7 interactions lead to the induction of indoleamine 2,3-dioxygenase in tolergenic dendritic cell (DC) populations (42, 44). Thus, loss of CTLA-4 would lead to a T-cell defect but would also result in the loss of tolergenic DCs, leading to a more severe form of immune dysregulation. The implication of the DNA microarray data is that PD-1 engagement interferes with more pathways required for T-cell activation than does CTLA-4 engagement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next